Table 4 Medication use at enrollment; PSOLAR psoriasis patients
Psoriasis patients self-reporting PsA, established by a HCPa (N = 1719) | Psoriasis patients self-reporting PsAb (N = 4315) | Patients with psoriasis onlyc (N = 7775) | All PSOLAR patientsd (N = 12,090) | |
|---|---|---|---|---|
Patients with data, N | 1714 | 4306 | 7762 | 12,068 |
Systemic steroids | 566 (33.0)* | 1284 (29.8)* | 1548 (19.9) | 2832 (23.5) |
Retinoids and/or combination topical | 760 (44.3) | 2001 (46.5)* | 3285 (42.3) | 5286 (43.8) |
Taclonex | 367 (21.4) | 1146 (26.6) | 1804 (23.2) | 2950 (24.4) |
Acitretin | 406 (23.7) | 921 (21.4) | 1506 (19.4) | 2427 (20.1) |
Tazorac | 164 (9.6) | 561 (13.0) | 758 (9.8) | 1319 (10.9) |
Etretinate | 25 (1.5) | 50 (1.2) | 53 (0.7) | 103 (0.9) |
Patients with NSAID data, N | 1718 | 4310 | 7769 | 12,079 |
NSAIDs | 835 (48.6)* | 1702 (39.5)* | 540 (7.0) | 2242 (18.6) |
Sulfasalazine | 112 (6.5) | 162 (3.8) | 26 (0.3) | 188 (1.6) |
Other NSAIDs | 781 (45.5) | 1626 (37.7) | 520 (6.7) | 2146 (17.8) |
Immunomodulators | 1193 (69.6)* | 2567 (59.6)* | 3221 (41.5) | 5788 (48.0) |
Methotrexate | 1104 (64.4) | 2326 (54.0) | 2634 (33.9) | 4960 (41.1) |
Cyclosporine | 339 (19.8) | 738 (17.1) | 1161 (15.0) | 1899 (15.7) |
Oral Tacrolimus | 1 (0.1) | 3 (0.1) | 4 (0.1) | 7 (0.1) |
Mycophenolate mofetil | 10 (0.6) | 25 (0.6) | 22 (0.3) | 47 (0.4) |
Other Immunomodulators | 60 (3.5) | 131 (3.0) | 147 (1.9) | 278 (2.3) |
Any biologic medications | 1464 (85.2)* | 3603 (83.5)* | 5164 (66.4) | 8767 (72.5) |
History of biologic medications at entry | ||||
Etanercept | 893 (51.9) | 2305 (53.4) | 2581 (33.2) | 4886 (40.4) |
Adalimumab | 678 (39.4) | 1673 (38.8) | 1890 (24.3) | 3563 (29.5) |
Infliximab | 477 (27.7) | 1037 (24.0) | 895 (11.5) | 1932 (16.0) |
Ustekinumab | 378 (22.0) | 703 (16.3) | 1569 (20.2) | 2272 (18.8) |
Efalizumab | 147 (8.6) | 452 (10.5) | 892 (11.5) | 1344 (11.1) |
Alefacept | 96 (5.6) | 272 (6.3) | 428 (5.5) | 700 (5.8) |
Golimumab | 32 (1.9) | 44 (1.0) | 2 (0.0) | 46 (0.4) |
Other | 48 (2.8) | 87 (2.0) | 147 (1.9) | 234 (1.9) |
Number of biologic medications used prior to entry | ||||
0 | 255 (14.8)* | 712 (16.5)* | 2611 (33.6) | 3323 (27.5) |
1 | 682 (39.7) | 1734 (40.2) | 2992 (38.5) | 4726 (39.1) |
2 | 445 (25.9) | 1097 (25.4) | 1366 (17.6) | 2463 (20.4) |
3 | 222 (12.9) | 525 (12.2) | 592 (7.6) | 1117 (9.2) |
≥ 4 | 115 (6.7) | 247 (5.7) | 214 (2.8) | 461 (3.8) |
Topical therapy | 1668 (97.3) | 4207 (97.7)* | 7485 (96.4) | 11,692 (96.9) |
Topical steroid therapy | 1637 (95.5) | 4142 (96.2) | 7325 (94.4) | 11,467 (95.0) |
High potency | 1373 (80.1) | 3607 (83.8) | 6156 (79.3) | 9763 (80.9) |
Medium potency | 1049 (61.2) | 2680 (62.2) | 4481 (57.7) | 7161 (59.3) |
Low potency | 707 (41.2) | 1826 (42.4) | 2749 (35.4) | 4575 (37.9) |
Phototherapy | 1028 (60.0)* | 2411 (56.0)ns | 4172 (53.7) | 6583 (54.5) |
Psoralens + UVA | 417 (24.3) | 860 (20.0) | 1207 (15.6) | 2067 (17.1) |
UVB | 833 (48.6) | 2000 (46.4) | 3524 (45.4) | 5524 (45.8) |
Laser | 29 (1.7) | 56 (1.3) | 129 (1.7) | 185 (1.5) |